Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 538

1.

Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.

Ozaki N, Ohmuraya M, Ida S, Hashimoto D, Ikuta Y, Chikamoto A, Hirota M, Baba H.

J Hepatobiliary Pancreat Sci. 2013 Aug;20(6):620-7. doi: 10.1007/s00534-012-0587-6.

PMID:
23475261
2.

Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor.

Ozaki N, Ohmuraya M, Hirota M, Ida S, Wang J, Takamori H, Higashiyama S, Baba H, Yamamura K.

Mol Cancer Res. 2009 Sep;7(9):1572-81. doi: 10.1158/1541-7786.MCR-08-0567. Epub 2009 Sep 8.

3.

Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence.

Biankin AV, Kench JG, Biankin SA, Lee CS, Morey AL, Dijkman FP, Coleman MJ, Sutherland RL, Henshall SM.

Am J Surg Pathol. 2004 Sep;28(9):1184-92.

PMID:
15316318
4.

Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas.

Oda Y, Aishima S, Morimatsu K, Hayashi A, Shindo K, Fujino M, Mizuuchi Y, Hattori M, Tanaka M, Oda Y.

Hum Pathol. 2013 Aug;44(8):1487-98. doi: 10.1016/j.humpath.2012.12.001. Epub 2013 Mar 1.

PMID:
23465281
5.
6.

[Intraepithelial neoplasms (PanIN) and intraductal papillary-mucinous neoplasms (IPMN) of the pancreas as precursor lesions of pancreatic carcinoma].

Ott C, Heinmöller E, Gaumann A, Schölmerich J, Klebl F.

Med Klin (Munich). 2007 Feb 15;102(2):127-35. Review. German.

PMID:
17323019
7.

Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma.

Fukuda A.

J Hepatobiliary Pancreat Sci. 2015 Jul;22(7):519-23. doi: 10.1002/jhbp.246. Epub 2015 Apr 21. Review.

8.

Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.

Furukawa T, Fujisaki R, Yoshida Y, Kanai N, Sunamura M, Abe T, Takeda K, Matsuno S, Horii A.

Mod Pathol. 2005 Aug;18(8):1034-42.

9.

Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.

Adsay NV, Basturk O, Cheng JD, Andea AA.

Semin Radiat Oncol. 2005 Oct;15(4):254-64. Review.

PMID:
16183479
10.

The pathology of ductal-type pancreatic carcinomas and pancreatic intraepithelial neoplasia: insights for clinicians.

Klöppel G, Lüttges J.

Curr Gastroenterol Rep. 2004 Apr;6(2):111-8. Review.

PMID:
15191688
11.

Different patterns of p16INK4A and p53 protein expressions in intraductal papillary-mucinous neoplasms and pancreatic intraepithelial neoplasia.

Abe K, Suda K, Arakawa A, Yamasaki S, Sonoue H, Mitani K, Nobukawa B.

Pancreas. 2007 Jan;34(1):85-91.

PMID:
17198188
12.

Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.

Motoda N, Matsuda Y, Onda M, Ishiwata T, Uchida E, Naito Z.

Int J Oncol. 2011 Jan;38(1):133-43.

PMID:
21109934
13.

EZH2 is associated with malignant behavior in pancreatic IPMN via p27Kip1 downregulation.

Kuroki H, Hayashi H, Okabe H, Hashimoto D, Takamori H, Nakahara O, Nakagawa S, Fukushima Y, Chikamoto A, Beppu T, Hirota M, Iyama K, Baba H.

PLoS One. 2014 Aug 1;9(8):e100904. doi: 10.1371/journal.pone.0100904. eCollection 2014.

14.

Progressive genomic alterations in intraductal papillary mucinous tumours of the pancreas and morphologically similar lesions of the pancreatic ducts.

Soldini D, Gugger M, Burckhardt E, Kappeler A, Laissue JA, Mazzucchelli L.

J Pathol. 2003 Apr;199(4):453-61.

PMID:
12635136
15.

Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of Twist expression in pancreatic juice.

Ohuchida K, Mizumoto K, Ohhashi S, Yamaguchi H, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M.

Int J Cancer. 2007 Apr 15;120(8):1634-40.

16.

Clinical role of Notch signaling pathway in intraductal papillary mucinous neoplasm of the pancreas.

Ikemoto T, Sugimoto K, Shimada M, Utsunomiya T, Morine Y, Imura S, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Yamada S.

J Gastroenterol Hepatol. 2015 Jan;30(1):217-22. doi: 10.1111/jgh.12660.

PMID:
25041344
17.

EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.

Park SJ, Gu MJ, Lee DS, Yun SS, Kim HJ, Choi JH.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8298-304. eCollection 2015.

18.

Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm.

Tanaka T, Kuroki T, Adachi T, Ono S, Hirabaru M, Soyama A, Kitasato A, Takatsuki M, Hayashi T, Eguchi S.

Pancreas. 2013 Apr;42(3):488-93. doi: 10.1097/MPA.0b013e318269d281.

PMID:
23146920
19.

Expression of MSX2 predicts malignancy of branch duct intraductal papillary mucinous neoplasm of the pancreas.

Satoh K, Hamada S, Kanno A, Hirota M, Umino J, Ito H, Masamune A, Egawa S, Unno M, Shimosegawa T.

J Gastroenterol. 2010 Jul;45(7):763-70. doi: 10.1007/s00535-010-0200-1. Epub 2010 Jan 28.

PMID:
20107842
20.

Where and when does pancreatic carcinoma start?

Lüttges J, Hahn S, Klöppel G.

Med Klin (Munich). 2004 Apr 15;99(4):191-5.

PMID:
15085289

Supplemental Content

Support Center